CSF biomarkers for mild cognitive impairment

Journal of Internal Medicine

Volumn 256, Issue 3, 2004, Pages 224-234

  Blennow, K ^a  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

amyloid; Alzheimer's disease; Biomarkers; Cerebrospinal fluid; Diagnosis; Tau proteins

Indexed keywords

AMYLOID BETA PROTEIN; TAU PROTEIN;

AGING; ALZHEIMER DISEASE; AMINO ACID SEQUENCE; CEREBROSPINAL FLUID; CEREBROSPINAL FLUID ANALYSIS; CLINICAL EXAMINATION; COGNITIVE DEFECT; CONFERENCE PAPER; DEMENTIA; DEPRESSION; DIAGNOSTIC ACCURACY; DIAGNOSTIC PROCEDURE; DIFFERENTIAL DIAGNOSIS; DIFFUSE LEWY BODY DISEASE; DISEASE SEVERITY; FRONTOTEMPORAL DEMENTIA; HUMAN; LABORATORY TEST; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN ANALYSIS; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

AGED; ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; BIOLOGICAL MARKERS; COGNITION DISORDERS; DISEASE PROGRESSION; HUMANS; TAU PROTEINS;

EID: 4544266973     PISSN: 09546820     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2796.2004.01368.x     Document Type: Conference Paper

References (100)

1. Blennow K, Skoog I. Genetic testing for Alzheimer's disease: how close is reality? Curr Opin Psychiatry 1999; 12: 487-93.
2. Tomlinson BE, Blessed G, Roth M. Observations on the brains of demented old people. J Neurol Sci 1970; 11: 205-42.
3. Davies L, Wolska B, Hilbich C et al. A4 amyloid protein deposition and the diagnosis of Alzheimer's disease: prevalence in aged brains determined by immunocytochemistry compared with conventional neuropathologic techniques. Neurology 1988; 38: 1688-93.
4. Petersen RC, Smith GE, Waring SC, Ivnik RJ, Tangalos EG, Kokmen E. Mild cognitive impairment: clinical characterization and outcome. Arch Neurol 1999; 56: 303-8.
5. DeCarli C. Mild cognitive impairment: prevalence, prognosis, aetiology, and treatment. Lancet Neurol 2003; 2: 15-21.
6. Blennow K, Wallin A. Clinical heterogeneity of probable Alzheimer's disease. J Geriatr Psychiatry Neurol 1992; 5: 106-13.
7. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of department of health and human services task force on Alzheimer's disease. Neurology 1984; 34: 939-44.
8. Galasko D, Hansen LA, Katzman R et al. Clinical-neuropathological correlations in Alzheimer's disease and related dementias. Arch Neurol 1994; 51: 888-95.
9. Jellinger KA. Diagnostic accuracy of Alzheimer's disease; a clinicopathological study. Acta Neuropathol 1996; 91: 219-20.
10. Buée L, Bussiere T, Buee-Scherrer V, Delacourte A, Hof PR. Tau protein isoforms, phosphorylation and role in neurodegenerative disorders. Brain Res Brain Res Rev 2000; 33: 95-130.
11. Grundke-Iqbal I, Iqbal K, Tung YC, Quinlan M, Wisniewski HM, Binder LI. Abnormal phosphorylation of the microtubule-associated protein τ (tau) in Alzheimer cytoskeletal pathology. Proc Natl Acad Sci U S A 1986; 83: 4913-7.
12. Iqbal K, Alonso AD, Gondal JA et al. Mechanism of neurofibrillary degeneration and pharmacologic therapeutic approach. J Neural Transm Suppl 2000; 59: 213-22.
13. Vandermeeren M, Mercken M, Vanmechelen E et al. Detection of τ proteins in normal and Alzheimer's disease cerebrospinal fluid with a sensitive sandwich enzyme-linked immunosorbent assay. J Neurochem 1993; 61: 1828-34.
14. Blennow K, Wallin A, Ågren H, Spenger C, Siegfried J, Vanmechelen E. Tau protein in cerebrospinal fluid: a biochemical diagnostic marker for axonal degeneration in Alzheimer's disease? Mol Chem Neuropathol 1995; 26: 231-45.
15. Vigo-Pelfrey C, Seubert P, Barbour R et al. Elevation of microtubule-associated protein tau in the cerebrospinal fluid of patients with Alzheimer's disease. Neurology 1995; 45: 788-93.
16. Blennow K, Vanmechelen E, Hampel H. CSF total tau. Ab42 and phosphorylated tau protein as biomarkers for Alzheimer's disease. Mol Neurobiol 2001; 24: 87-97.
17. Hesse C, Rosengren L, Vanmechelen E et al. Cerebrospinal fluid markers for Alzheimer's disease evaluated after acute ischemic stroke. J Alzheimer Dis 2000; 2: 199-206.
18. Otto M, Wiltfang J, Tumani H et al. Elevated levels of tau-protein in cerebrospinal fluid of patients with Creutzfeldt-Jakob disease. Neurosci Lett 1997; 225: 210-2.
19. Andreasen N, Minthon L, Clarberg A et al. Sensitivity, specificity and stability of CSF t-tau in AD in a community-based patient sample. Neurology 1999; 53: 1488-94.
20. Vanmechelen E, Vanderstichele H, Davidsson P et al. Quantification of tau phosphorylated at threonine 181 in human cerebrospinal fluid: a sandwich ELISA with a synthetic phosphopeptide for standardization. Neurosci Lett 2000; 285: 49-52.
21. Ishiguro K, Ohno H, Arai H et al. Phosphorylated tau in human cerebrospinal fluid is a diagnostic marker for Alzheimer's disease. Neurosci Lett 1999; 270: 91-4.
22. Kohnken R, Buerger K, Zinkowski R et al. Detection of tau phosphorylated at threonine 231 in cerebrospinal fluid of Alzheimer's disease patients. Neurosci Lett 2000; 287: 187-90.
23. Hu YY, He SS, Wang X et al. Levels of nonphosphorylated and phosphorylated tau in cerebrospinal fluid of Alzheimer's disease patients: an ultrasensitive bienzyme-substrate-recycle enzyme-linked immunosorbent assay. Am J Pathol 2002; 160: 1269-78.
24. Hesse C, Rosengren L, Andreasen N et al. Transient increase in CSF total tau but not phospho-tau after acute stroke. Neurosci Lett 2001; 297: 187-90.
25. Riemenschneider M, Wagenpfeil S, Vanderstichele H et al. Phospho-tau/total tau ratio in cerebrospinal fluid discriminates Creutzfeldt-Jakob disease from other dementias. Mol Psychiatry 2003; 8: 343-7.
26. Masters CL, Simms G, Weinman NA, Multhaup G. McDonald BL, Beyreuther K. Amyloid plaque core protein in Alzheimer's disease and Down syndrome. Proc Natl Acad Sci USA 1985; 82: 4245-9.
27. Haas C, Selkoe DJ. Cellular processing of beta-amyloid precursor protein and the genesis of amyloid beta-peptide. Cell 1993; 75: 1039-42.
28. Kang J, Lemaire HG, Unterbeck A et al. The precursor of Alzheimer's disease amyloid A4 protein resembles a cell-surface receptor. Nature 1987; 325: 733-6.
29. Buxbaum JD, Liu KN, Luo Y et al. Evidence that tumor necrosis factor alpha converting enzyme is involved in regulated alpha-secretase cleavage of the Alzheimer amyloid protein precursor. J Biol Chem 1998; 273: 27765-7.
30. Lammich S, Kojro E, Postina R et al. Constitutive and regulated alpha-secretase cleavage of Alzheimer's amyloid precursor protein by a disintegrin metalloprotease. Proc Natl Acad Sci U S A 1999; 96: 3922-7.
31. Wolfe MS, Xia W, Ostaszewski BL, Diehl TS, Kimberly WT. Selkoe DJ. Two transmembrane aspartates in presenilin-1 required for presenilin endoproteolysis and gamma-secretase activity. Nature 1999; 398: 513-7.
32. Li YM, Xu M, Lai MT et al. Photoactivated gamma-secretase inhibitors directed to the active site covalently label presenilin 1. Nature 2000; 405: 689-94.
33. Yu G, Nishimura M, Arawaka S et al. Nicastrin modulates presenilin-mediated notch/glp-1 signal transduction and betaAPP processing. Nature 2000; 407: 48-54.
34. Francis R, McGrath G, Zhang J et al Aph-1 and pen-2 are required for Notch pathway signaling, gamma-secretase cleavage of beta-APP, and presenilin protein accumulation. Dev Cell 2002; 3: 85-97.
35. Goutte C, Tsunozaki M, Hale VA, Priess JR. APH-1 is a multipass membrane protein essential for the Notch signaling pathway in Caenorhabditis elegans embryos. Proc Natl Acad Sci U S A 2002; 99: 775-9.
36. Vassar R, Bennett BD, Babu-Khan S et al. Beta-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE. Science 1999; 286: 735-41.
37. Van Nostrand WE, Wagner SL, Shankle WR et al. Decreased levels of soluble amyloid beta-protein precursor in cerebrospinal fluid of live Alzheimer disease patients. Proc Natl Acad Sci U S A 1992; 89: 2551-5.
38. Farlow M, Ghetti B, Benson MD, Farrow JS, van Nostrand WE, Wagner SL. Low cerebrospinal-fluid concentrations of soluble amyloid beta-protein precursor in hereditary Alzheimer's disease. Lancet 1992; 340: 453-4.
39. Tabaton M, Nunzi MG, Xue R, Usiak M, Autilio-Gambetti L, Gambetti P. Soluble amyloid beta-protein is a marker of Alzheimer amyloid in brain but not in cerebrospinal fluid. Biochem Biophys Res Commun 1994; 200: 1598-603.
40. van Gool WA, Kuiper MA, Walstra GJ, Wolters EC, Bolhuis PA. Concentrations of amyloid beta protein in cerebrospinal fluid of patients with Alzheimer's disease. Ann Neurol 1995; 37: 277-9.
41. Motter R, Vigo-Pelfrey C, Kholodenko D et al. Reduction of β-amyloid peptide42 in the cerebrospinal fluid of patients with Alzheimer's disease. Ann Neurol 1995; 38: 643-8.
42. Southwick PC, Yamagata SK, Echols CL et al. Assessment of amyloid beta protein in cerebrospinal fluid as an aid in the diagnosis of Alzheimer's disease. J Neurochem 1996; 66: 259-65.
43. Jarrett JT, Berger EP, Lansbury PT. The carboxy terminus of the beta amyloid protein is critical for the seeding of amyloid formation: implications for the pathogenesis of Alzheimer's disease. Biochemistry 1993; 32: 4693-7.
44. Iwatsubo T, Odaka A, Suzuki N, Mizusawa H, Nukina N, Ihara Y. Visualization of Aβ42(43) and Aβ40 in senile plaques with end-specific Aβ monocloncals: evidence that an initially deposited species is Aβ42(43). Neuron 1994; 13: 45-53.
45. Tamaoka A, Kondo T, Odaka A et al. Biochemical evidence for the long-tail form (Aβ 1-42/43) of amyloid β protein as a seed molecule cerebral deposits of Alzheimer's disease. Biochem Biophys Res Commun 1994; 205: 834-42.
46. (1-42) in CSF. In: Fisher A, Hanin I, Yoshida M, eds. Progress in Alzheimer's and Parkinsons Diseases. New York: Plenum Press. 1998: 773-8.
47. Otto M, Esselmann H, Schulz-Shaeffer W et al. Decreased beta-amyloid1-42 in cerebrospinal fluid of patients with Creutzfeldt-Jakob disease. Neurology 2000; 54: 1099-102.
48. Sjögren M, Davidsson P, Wallin A et al. Decreased CSF β-amyloid42 in Alzheimer's disease and amyotrophic lateral sclerosis may reflect mismetabolism of β-amyloid induced by separate mechanisms. Dement Geriatr Cogn Disord 2002; 13: 112-8.
49. Holmberg B, Johnels B, Blennow K, Rosengren L. Cerebrospinal fluid Abeta42 is reduced in multiple system atrophy but normal in Parkinson's disease and progressive supranuclear palsy. Mov Disord 2003; 18: 186-90.
50. Strozyk D, Blennow K, White LR, Launer LJ. CSF Aβ42 levels correlate with amyloid-neuropathology in a population-based autopsy study. Neurology 2003; 60: 652-6.
51. Tamaoka A, Sawamura N, Fukushima T et al. Amyloid beta protein 42(43) in cerebrospinal fluid of patients with Alzheimer's disease. J Neurol Sci 1997; 148: 41-5.
52. Kanai M, Matsubara E, Isoe K et al. Longitudinal study of cerebrospinal fluid levels of tau. A betal-40, and A betal-42(43) in Alzheimer's disease: a study in Japan. Ann Neurol 1998; 44: 17-26.
53. Shoji M, Matsubara E, Kanai M et al. Combination assay of CSF tau, A beta 1-40 and A beta 1-42(43) as a biochemical marker of Alzheimer's disease. J Neurol Sci 1998; 158: 134-40.
54. Fukuyama R, Mizuno T, Mori S, Nakajima K, Fushiki S, Yanagisawa K. Age-dependent change in the levels of Abeta40 and Abeta42 in cerebrospinal fluid from control subjects, and a decrease in the ratio of Abeta42 to Abeta40 level in cerebrospinal fluid from Alzheimer's disease patients. Eur Neurol 2000; 43: 155-60.
55. Mehta PD, Pirttila T, Mehta SP, Sersen EA, Aisen PS, Wisniewski HM. Plasma and cerebrospinal fluid levels of amyloid beta proteins 1-40 and 1-42 in Alzheimer disease. Arch Neurol 2000; 57: 100-5.
56. Vigo-Pelfrey C, Lee D, Keim P, Lieberburg I, Schenk DB. Characterization of beta-amyloid peptide from human cerebrospinal fluid. J Neurochem 1993; 61: 1965-8.
57. Wiltfang J, Esselmann H, Bibl M et al. Highly conserved and disease-specific patterns of carboxy-terminally truncated Abeta peptides 1-37/38/39 in addition to 1-40/42 in Alzheimer's disease and in patients with chronic neuroinflammation. J Neurochem 2002; 81: 481-96.
58. Lewczuk P, Esselmann H, Meyer M et al. The amyloid-beta (Abeta) peptide pattern in cerebrospinal fluid in Alzheimer's disease: evidence of a novel carboxyterminally elongated Abeta peptide. Rapid Commun Mass Spectrom 2003; 17: 1291-6.
59. Blennow K, Hampel H. Cerebrospinal fluid markers for incipient Alzheimer's disease. Lancet Neurol 2003; 2: 605-13.
60. Hulstaert F, Blennow K, Ivanoiu A et al. Improved discrimination of AD patients using beta-amyloid(1-42) and tau levels in CSF. Neurology 1999; 52: 1555-62.
61. Morikawa Y, Arai H, Matsushita S et al. Cerebrospinal fluid tau protein levels in demented and nondemented alcoholics. Alcohol Clin Exp Res 1999; 23: 575-7.
62. Kahle PJ, Jakowec M, Teipel SJ et al. Combined assessment of tau and neuronal thread protein in Alzheimer's disease CSF. Neurology 2000; 54: 1498-504.
63. Sjögren M, Minthon L, Davidsson P et al. CSF levels of tau, β-amyloid1-42 and GAP-43 in frontotemporal dementia, other types of dementia and normal aging. J Neural Transm 2000; 107: 563-79.
64. Sjögren M, Davidsson P, Gottfries J et al. The cerebrospinal fluid levels of tau, growth-associated protein-43 and soluble amyloid precursor protein correlate in Alzheimer's disease, reflecting a common pathophysiological process. Dement Geriatr Cogn Disord 2001; 12: 257-64.
65. Kosunen O, Soininen H, Paljärvi L, Heinonen O. Talasniemi S, Riekkinen PJ Sr. Diagnostic accuracy of Alzheimer's disease: a neuropathological study. Acta Neuropathol 1996; 91: 185-93.
66. Green AJ, Harvey RJ, Thompson EJ, Rossor MN. Increased tau in the cerebrospinal fluid of patients with frontotemporal dementia and Alzheimer's disease. Neurosci Lett 1999; 259: 133-5.
67. Sjögren M, Davidsson P, Tullberg M et al. Both total and hyperphosphorylated tau are increased in Alzheimer's disease. J Neurol Neurosurg Psychiatry 2001; 70: 624-30.
68. Buerger K, Zinkowski R, Teipel SJ et al. Differentiation of geriatric major depression from Alzheimer's disease with CSF tau protein phosphorylated at threonine 231. Am J Psychiatry 2003; 160: 376-9.
69. Buerger K, Zinkowski R, Teipel SJ et al. Differential diagnosis of Alzheimer's disease with cerebrospinal fluid levels of tau protein phosphorylated at threonine 231. Arch Neurol 2002; 59: 1267-72.
70. Itoh N, Arai H, Urakami K et al. Large-scale, multicenter study of cerebrospinal fluid tau protein phosphorylated at serine 199 for the antemortem diagnosis of Alzheimer's disease. Ann Neurol 2001; 50: 150-6.
71. Parnetti L, Lanari A, Amici S, Gallai V, Vanmechelen E, Hulstaert F. CSF phosphorylated tau is a possible marker for discriminating Alzheimer's disease from dementia with Lewy bodies. Phospho-Tau International Study Group. Neurol Sci 2001; 22: 77-8.
72. Hampel H, Buerger K, Zinkowski R et al. Measurement of phosphorylated tau epitopes in the differential diagnosis of Alzheimer disease: A Comparative Cerebrospinal Fluid Study. Arch Gen Psychiatry 2004; 61: 95-102.
73. (1-42) in Alzheimer's disease: differences between early- and late-onset Alzheimer disease and stability during the course of disease. Arch Neurol 1999b; 56: 673-80.
74. Kanemaru K, Kameda N, Yamanouchi H. Decreased CSF amyloid beta42 and normal tau levels in dementia with Lewy bodies. Neurology 2000; 54: 1875-6.
75. Riemenschneider M, Buch K, Schmolke M, Kurz A, Guder WG. Cerebrospinal protein tau is elevated in early Alzheimer's disease. Neurosci Lett 1996; 212: 209-11.
76. Galasko D, Clark C, Chang L et al. Assessment of CSF levels of tau protein in mildly demented patients with Alzheimer's disease. Neurology 1997; 48: 632-5.
77. Galasko D, Chang L, Motter R et al. High cerebrospinal fluid tau and low amyloid beta42 levels in the clinical diagnosis of Alzheimer disease and relation to apolipoprotein E genotype. Arch Neurol 1998; 55: 937-45.
78. Kurz A, Riemenschneider M, Buch K et al. Tau protein in cerebrospinal fluid is significantly increased at the earliest stage of Alzheimer disease. Alzheimer Dis Assoc Disord 1998; 12: 372-7.
79. Andreasen N, Minthon L, Vanmechelen E et al. CSF t-tau and CSF-Aβ42 as predictors of development of Alzheimer's disease in patients with mild cognitive impairment. Neurosci Lett 1999; 273: 5-8.
80. Andreasen N, Minthon L, Davidsson P, Vanmechelen E, Vanderstichele H, Winblad B, Evaluation of CSF-tau and CSF-Aβ42 as diagnostic markers for Alzheimer's disease in clinical practice. Arch Neurol 2001; 58: 373-9.
81. Andreasen N, Vanmechelen E, Vanderstichele H, Davidsson P, Blennow K. Cerebrospinal fluid levels of total-tau, phospho-tau and Aβ42 predicts development of Alzheimer's disease in patients with mild cognitive impairment. Acta Neurol Scand 2003; 107(Suppl. 179): 47-51.
82. Arai H, Ishiguro K, Ohno H et al. CSF phosphorylated tau protein and mild cognitive impairment: a prospective study. Exp Neurol 2000; 166: 201-3.
83. Riemenschneider M, Lautenschlager N, Wagenpfeil S, Diehl J, Drzezga A, Kurz A. Cerebrospinal fluid tau and beta-amyloid 42 proteins identify Alzheimer disease in subjects with mild cognitive impairment. Arch Neurol 2002; 59: 1729-34.
84. Lautenschlager NT, Riemenschneider M, Drzezga A. Primary degenerative mild cognitive impairment: study population, clinical, brain imaging and biochemical findings. Dement Geriatr Cogn Disord 2001; 12: 379-86.
85. Gottfries J, Blennow K, Lehmann MW, Regland B, Gottfries CG. One-carbon metabolism and other biochemical correlates of cognitive impairment as visualized by principal component analysis. J Geriatr Psychiatry Neurol 2001; 14: 109-14.
86. Maruyama M, Arai H, Sugita M et al. Cerebrospinal fluid amyloid beta(1-42) levels in the mild cognitive impairment stage of Alzheimer's disease. Exp Neurol 2001; 172: 433-6.
87. Arai H, Nakagawa T, Kosaka Y et al. Elevated Cerebrospinal fluid tau protein level as a predictor of dementia in memory-impaired patients. Alzheimer's Res 1997; 3: 211-3.
88. Buerger K, Teipel SJ, Zinkowski R et al. CSF tau protein phosphorylated at threonine 231 correlates with cognitive decline in MCI subjects. Neurology 2002; 59: 627-9.
89. Skoog I, Davidsson P, Aevarsson O, Vanderstichele H, Vanmechelen E, Blennow K. Cerebrospinal fluid beta-amyloid 42 is reduced before the onset of sporadic dementia: a population-based study in 85-year-olds. Dement Geriatr Cogn Disord 2003; 15: 169-76.
90. Price JL, Morris JC. Tangles and plaques in nondemented aging and 'preclinical' Alzheimer's disease. Ann Neurol 1999; 45: 358-68.
91. 1-42 and increased tau levels in cerebrospinal fluid of patients with Alzheimer disease. JAMA 2003; 289: 2094-103.
92. Vandam LD, Dripps RD, Long-term follow-up of patients who received 10 098 spinal anesthetics. JAMA 1956; 161: 586-91.
93. Blennow K, Wallin A, Hager O. Low frequency of post-lumbar puncture headache in demented patients. Acta Neurol Scand 1993; 88: 221-3.
94. Blennow K, Wallin A, Gottfries CG, Månsson JE, Svennerholm L. Concentration gradients for monoamine metabolites in lumbar cerebrospinal fluid. J Neural Transm 1993; 5: 5-15.
95. Blennow K, Fredman P, Wallin A, Gottfries CG, Långström L, Svennerholm L. Protein analyses in cerebrospinal fluid: I. Influence of concentration gradients for proteins on cerebrospinal fluid/serum albumin ratio. Eur Neurol 1993; 33: 126-8.
96. Blennow K, Wallin A, Chong JK. Cerebrospinal fluid 'neuronal thread protein' comes from serum by passage over the blood-brain barrier. Neurodegeneration 1995; 4: 187-93.
97. Blennow K, Skoog I, Wallin A, Wikkelsö C, Fredman P. Immunoglobulin M in cerebrospinal fluid: reference values derived from 111 healthy individuals 18-88 years of age. Eur Neurol 1996; 36: 201-5.
98. Hesse C, Larsson H, Fredman P et al. Measurement of apolipoprotein E (apoE) in cerebrospinal fluid. Neurochem Res 2000; 25: 511-7.
99. Zakzanis KK, Graham SJ, Campbell Z. A meta-analysis of structural and functional brain imaging in dementia of the Alzheimer's type: a neuroimaging profile. Neuropsychol Rev 2003; 13: 1-18.
100. Wolf H, Jelic V, Gertz HJ, Nordberg A, Julin P, Wahlund LO. A critical discussion of the role of neuroimaging in mild cognitive impairment. Acta Neurol Scand Suppl 2003; 179: 52-76.